secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001104659-24-130812
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h
--------------------------------------------------------------------------------

- Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
- Cohort 3 dose will be approximately double the Cohort 2 dose; enrollment ongoing.
- Cohort 1 PK/PD data consistent with preclinical and Phase 0; 66% miR-10b inhibition at 24h post-infusion.
- Plasma concentration of TTX-MC138 in humans exceeded nonclinical levels, suggesting favorable PK.
- Several patients from Cohorts 1 and 2 remain on study for continued treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924130812/0001104659-24-130812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924130812/tm2431511d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-130812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer